Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma

PURPOSE: Crizotinib, the first FDA-approved ALK inhibitor, showed significant antitumor activity in young patients with anaplastic large-cell lymphoma (ALCL) frequently displaying ALK rearrangement. However, long-term therapeutic benefits of crizotinib are limited due to development of drug resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Zdzalik, Daria, Dymek, Barbara, Grygielewicz, Paulina, Gunerka, Pawel, Bujak, Anna, Lamparska-Przybysz, Monika, Wieczorek, Maciej, Dzwonek, Karolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949014/
https://www.ncbi.nlm.nih.gov/pubmed/24509625
http://dx.doi.org/10.1007/s00432-014-1589-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949014/
https://www.ncbi.nlm.nih.gov/pubmed/24509625
http://dx.doi.org/10.1007/s00432-014-1589-3

Ejemplares similares